[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629746":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":47,"collaborators":11,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":11,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":11,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":72,"whyStopped":11,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"University of Chicago","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Radiation treatment","EXPERIMENTAL",null,[13],"Radiation: Low dose radiation therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"RADIATION","Low dose radiation therapy","0.5 Gy per treatment x 6 treatments, given 2-3 treatments per week over 2-3 weeks (Can be given concurrently with IO)",[9],[21],{"name":22,"affiliation":5,"role":23},"Pankti Reid","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"Clinical Trials Intake","CONTACT","855-702-8222","cancerclinicaltrials@bsd.uchicago.edu",[31],{"facility":32,"status":11,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"The University of Chicago Medicine Comprehensive Cancer Center","Chicago","Illinois","60637","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-87.65005,41.85003,{"lat":42,"lon":41},[45,46],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},{"name":22,"role":23,"phone":11,"phoneExt":11,"email":11},{"type":48,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100629746","phase-1-radiation-to-treat-joint-damage-caused-by-cancer-immunotherapy-100629746",false,"NCT07478679","Radiation to Treat Joint Damage Caused by Cancer Immunotherapy","Use of Low-Dose RADiotherapy in the Management of Immune Checkpoint- Inhibitor-ArThropathy as an Immune-Related Adverse Event (RADIATE)","Inclusion Criteria:\n\n* Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which they are receiving single agent or combination immunotherapy or within the last 6 months.\n* Rheumatologist-established diagnosis of new onset CTCAE grade 2-3 immunotherapy-induced inflammatory arthritis or activated osteoarthritis, involving one or more joints (up to 3) including but not limited to hands, shoulders, elbows, hips, knees and ankles.\n* Age ≥ 40 years.\n* ECOG performance status ≤2 (Karnofsky ≥60%).\n* Patients with ability and willingness to sign consent.\n\nExclusion Criteria:\n\n* Contraindications to radiation treatment, such as pregnancy, breast-feeding women and active collagen-vascular disease.\n* Women of child-bearing potential who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was \\>1 year prior to consent and\u002For clear documentation states that the patient is peri- or post-menopausal or there was recent supporting objective evidence of 'no pregnancy' status (e.g. blood or imaging) within 30 days prior to initiation of study treatment.\n* Have not received systemic steroids within the last 3 months for the treatment of immune related adverse events.\n* History of prior autoimmune conditions, or concurrent immune related adverse events requiring systemic immunosuppressants.\n* Estimated life expectancy less than 3 months as assessed by investigators.\n* Any condition at the discretion of investigator that will preclude participation in the study.\n* History of secondary malignancy as assessed by investigators.\n* History of radiation to affected joints as assessed by investigators.","ALL","40 Years",{"count":59,"type":60},20,"ESTIMATED","INTERVENTIONAL",[63],"PHASE1","This study will prospectively investigate the feasibility and safety of administering LDRT in patients with immunotherapy-induced inflammatory arthritis.",[66,67],"Arthritis","Arthropathy",[69,67,70,71],"Radiotherapy","Immunotherapy","Cancet","NOT_YET_RECRUITING","2026-03-18",{"date":75,"type":76},"2026-03-23","ACTUAL",{"date":78,"type":60},"2026-08-26",{"date":80,"type":60},"2028-09-17",{"name":5,"class":6},1]